TORUS SOFTWARE SOLUTIONS S.L.

Their core work

Torusware is a Spanish software SME based in A Coruña that builds high-performance computing and communications software, originally targeting financial services and big data infrastructure. Their first H2020 project (2014–2015) was their own SME Phase 1 venture developing low-latency, high-throughput communication systems for finance and large-scale data workloads. By 2018 they had pivoted — or extended — their data-processing capabilities into life sciences, participating as a third party in CONTRA, a Marie Skłodowska-Curie training network for computational oncology. In that context they likely contributed software tooling or HPC infrastructure to support computational cancer research rather than conducting the biology themselves.

What they specialise in

How they've shifted over time

In their first H2020 project (2014–2015) Torusware was squarely a fintech/big data software company, with no biological or medical dimension at all. By 2018 they had joined CONTRA, a cancer bioinformatics training network, where the surrounding research concerns somatic evolution, tumour cell morphology, and single-cell sequencing — topics that require heavy computational infrastructure rather than wet-lab work. The most plausible reading is that their HPC software competence transferred into the life-sciences sector as demand for large-scale genomic data processing grew, though the extent of their scientific depth in cancer biology remains unclear from the available data.

Torusware appears to be repositioning general-purpose HPC and data-communications software toward life-sciences use cases, making them potentially useful to consortia that need performant data pipelines for genomics or clinical data — provided their cancer-domain depth is confirmed directly.

How they like to work

Torusware has acted as consortium coordinator once (their own SME Phase 1 bid) and as a third-party contributor once (CONTRA), suggesting a pragmatic, opportunistic engagement style rather than a systematic consortium-building strategy. Their 14 partners across 7 countries mostly reflects CONTRA's wide ITN network rather than Torusware's own relationship capital. For a future partner, they would likely fit best as a specialist software or infrastructure provider rather than a scientific lead.

Torusware records 14 unique consortium partners across 7 countries, but this breadth is almost entirely attributable to the large CONTRA ITN network rather than organic relationship-building. Their own direct partnership history is thin and warrants direct outreach to verify active collaborations.

What sets them apart

Torusware occupies an unusual niche as a Spanish HPC software SME that has made a documented move from fintech data infrastructure into computational life sciences — a trajectory that few small software companies achieve. If their cancer-informatics involvement reflects genuine software product development (rather than a peripheral subcontract role), they sit at a genuinely underserved intersection of performance computing and biomedical data. For a consortium needing HPC-aware software development alongside cancer informatics expertise, they are worth investigating.

Highlights from their portfolio

• TORUS PROJECT
  Their own SME Phase 1 coordination demonstrates product-market fit in high-performance financial communications, showing the company can lead an EU-funded technology development effort independently.
• CONTRA
  Participation in a Marie Skłodowska-Curie Innovative Training Network on computational oncology signals an unusual sector pivot — a software SME providing infrastructure to a cancer bioinformatics research training programme.